Connect with us

CBD Infused Chewing Gum Being Tested on IBS Patients

Published

on

CBD InfusedIrritable Bowel Syndrome (IBS) affects between 25 and 45 million people in the United States. Doctors are now conducting a study to see if cannabis-infused gum can help people suffering from the ailment.

IBS is a disorder characterized by abdominal pain or discomfort and altered bowel habit. Doctors have been unable to effectively treat IBS, but a group of doctors at Wageningen University in the Netherlands claims that CBD, the non-psychoactive component of cannabis, could help alleviate the colon spasms that appear to be the root of the symptoms.

They will begin a clinical trial next month, testing cannabis-laced gum manufactured at the U.S. firm Medical Marijuana Inc. It will specifically test CanChew, a new product created by AXIM Biotechnologies.

The trial is a huge stepping stone in IBS research. IBS is responsible for $21 billion in medical expenses, missed work and overall loss of productivity. It is the most common disorder diagnosed by gastroenterologists. The ailment affects women more often, 60 percent of those afflicted are women.

“We are excited to see that AXIM has reached another milestone in its clinical development program,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “IBS is one of the most common disorders in the world affecting up to 15 percent of the global population, with no real treatment options available.”

There will be 40 participants in the trial, with ages ranging from 18 to 65, which have been diagnosed with IBS according to ROME III criteria. The gum will contain 50mg of CBD per serving, and participants will be permitted up to six pieces of gum a day.

“This is the first advancement in cannabinoid research for treatment of IBS in medical history and gives a clear example of how far ahead AXIM is in its clinical development programs,” said Titus.

AXIM also believes that their products will be able to help patients suffering from colitis and Crohn’s disease.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *